Perspectives in Vascular Surgery 2000; Volume 13(Number 1): 0071-0080
DOI: 10.1055/s-2000-9325
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel. +1(212)584-4662.

The Role of Cryopreserved Femoral Vein Graft in Hemodialysis Access Surgery

John H. Matsuura, David Rosenthal
  • Assistant Professor of Surgery, Medical College of Georgia; Associate Director of Vascular Surgery, Atlanta Medical Center, Atlanta, GA. (JHM); Professor of Surgery, Medical College of Georgia; Chief of Vascular Surgery, Atlanta Medical Center, Atlanta, GA (DR).
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

Preview

ABSTRACT

-Cryopreserved allografts have demonstrated resistance to infection similar to that of autogenous tissue when used for the treatment of prosthetic arterial bypass graft infections. As the number of hemodialysis access procedures increases, prosthetic hemodialysis graft infection has become a significant problem. We have used the cryopreserved femoral vein as an alternative conduit in the treatment of prosthetic arteriovenous (AV) hemodialysis graft infections. Forty-eight cryopreserved femoral vein AV graft procedures were performed. The 1-year primary graft patency rate was 49%, while the secondary graft patency rate was 75%. No subsequent cryopreserved allograft infections occurred. The cryopreserved femoral vein graft is a safe, durable, and infection resistant conduit for the treatment of prosthetic AV hemodialysis graft infections.